Transvaginal phosphodiesterase inhibitors for infertility treatment
AssigneeProkrea Bcn, S.L.
InventorsMaria Carmen Pardina Palleja, Miguel Angel Vaz-Romero Uña, Jose Maria Palacios Santibañez, Jose Luis Fabregas Vidal
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new application of phosphodiesterase inhibitors for couple infertility treatment which forms an effective alternative to the invasive assisted reproductive techniques such as conjugal artificial insemination and which consists of the transvaginal administration of a phosphodiesterase inhibitor immediately before and/or after coitus. It also relates to dosage forms suitable for the intravaginal administration of phosphodiesterase inhibitors.
Claims26
A pharmaceutical composition for treating infertility in a subject in need thereof comprising an effective amount of a phosphodiesterase inhibitor, a polyhydroxy alcohol, water in a proportion by weight of the pharmaceutical composition comprised between 75% and 95%, a carbomer and an alkaline agent, wherein the pharmaceutical composition is in the form of hydrophilic gel for transvaginal administration.
Dependencies are inferred from the claim text.